TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Immuron Limited ( (AU:IMC) ).
Immuron Limited has provided an update on its clinical trials for Travelan® and IMM-529. The company’s IND application for IMM-529, aimed at preventing or treating Clostridioides difficile infection, is under review by the FDA, with minor updates submitted following a request for additional information. Additionally, the release of topline data from the Travelan® P2TD study has been delayed due to a U.S. government shutdown, impacting the company’s dosing strategy for an upcoming FDA meeting. The outcomes of these trials are crucial for Immuron’s strategic planning and could influence its market positioning and stakeholder interests.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company that specializes in developing and commercializing orally delivered targeted polyclonal antibodies for treating infectious diseases.
Average Trading Volume: 198,447
Technical Sentiment Signal: Buy
Current Market Cap: A$23.97M
For an in-depth examination of IMC stock, go to TipRanks’ Overview page.